Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 29.18M 25.56M 23.57M 21.78M 41.3M 2.78B 41.98M 282M 110M 1.37B 110M 107M 4.72B P/E 2026 *
-1.1x
P/E 2027 * -1.66x
Enterprise Value 29.18M 25.56M 23.57M 21.78M 41.3M 2.78B 41.98M 282M 110M 1.37B 110M 107M 4.72B EV / Sales 2026 *
-
EV / Sales 2027 * 2.26x
Free-Float
97.65%
Yield 2026 *
-
Yield 2027 * -
06-03 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
06-01 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
06-01 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
05-29 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
05-29 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
05-08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
04-22 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
04-22 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
04-06 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
03-30 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-17 CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 CI
02-13 Actinium Pharmaceuticals, Inc. Announces Executive Changes, Effective as of February 27, 2026 CI
1 day-4.12%
1 week-5.20%
Current month-5.10%
1 month-11.43%
3 months-13.89%
6 months-33.09%
Current year-31.62%
1 week 0.92
Extreme 0.92
1.05
1 month 0.92
Extreme 0.92
1.11
Current year 0.92
Extreme 0.92
1.53
1 year 0.92
Extreme 0.92
1.89
3 years 0.92
Extreme 0.92
10.24
5 years 0.92
Extreme 0.92
15.12
10 years 0.92
Extreme 0.92
64.5
Manager TitleAgeSince
Chief Executive Officer 62 08/06/2017
Chief Tech/Sci/R&D Officer - 31/05/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 31/12/2007
Chairman 62 30/09/2013
Director/Board Member 68 07/11/2013
Date Insider Type Main position Quantity % Market Cap.
17/08/25Tax

Chief Executive Officer

120,900 0.3876%
30/03/25Issuer sale

Director

50,000 0.1603%
30/03/25Issuer sale

Director

184,984 0.5930%
Change 5-day change 1-year change 3-year change Capi.($)
-4.12%-5.20%-40.00%-87.23% 29.18M
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -1.02%-0.36%+44.88%+122.47% 24.12B
Weighted average by Cap. -0.91%-1.46%+55.03%+137.76%

Financials

2026 *2027 *
Net sales - 12.93M 11.33M 10.44M 9.65M 18.3M 1.23B 18.6M 125M 48.93M 607M 48.53M 47.48M 2.09B
Net income -28.5M -24.97M -23.02M -21.27M -40.34M -2.72B -41.01M -275M -108M -1.34B -107M -105M -4.61B -23.27M -20.39M -18.8M -17.37M -32.93M -2.22B -33.48M -225M -88.07M -1.09B -87.36M -85.46M -3.76B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
25
Date Price Change Volume
10/07/26 US$0.9300 -4.12% 75,891
09/07/26 US$0.9700 0.00% 51,156
08/07/26 US$0.9700 -7.62% 72,605
07/07/26 US$1.050 +9.26% 228,039
06/07/26 US$0.9610 -2.04% 144,720
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9300USD
Average target price
5.000USD
Spread / Average Target
+437.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock